ArticleInternational journal of clinical and experimental pathology2013
A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
Article in International journal of clinical and experimental pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Tumour-associated CD204Neuropathology and applied neurobiology · 2022Article
- Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells.Scientific reports · 2021Article
- Article
- Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.Journal of neuro-oncology · 2020Article
- Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.Journal of neuropathology and experimental neurology · 2019Article
- Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival.Scientific reports · 2018Article
- Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification.Diagnostic pathology · 2018Article
- High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma.Journal of neuro-oncology · 2018Article
- Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.BMC cancer · 2018Article
- Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response.Disease markers · 2018Review
- Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry.Journal of neuro-oncology · 2017Article
- Expression and prognostic value of JAM-A in gliomas.Journal of neuro-oncology · 2017Article
- Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.PloS one · 2017Article
- A 4-miRNA signature to predict survival in glioblastomas.PloS one · 2017Article
- APNG as a prognostic marker in patients with glioblastoma.PloS one · 2017Article
- The Danish Neuro-Oncology Registry: establishment, completeness and validity.BMC research notes · 2016Article
- Expression and prognostic value of the WEE1 kinase in gliomas.Journal of neuro-oncology · 2016Article
- Article
- Establishment and Characterization of a Tumor Stem Cell-Based Glioblastoma Invasion Model.PloS one · 2016Article
- High levels of c-Met is associated with poor prognosis in glioblastoma.Journal of neuro-oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledHigh-grade gliomas have a dismal prognosis, and prognostic factors are needed to optimize treatment algorithms. In this study we identified clinical prognostic factors as well as the prognostic value of isocitrate dehydrogenase 1 (IDH1) status in a population-based group of patients with high-grade gliomas. Using the Danish Cancer Registry and the Danish Pathology Databank we identified 359 patients: 234 had WHO grade IV gliomas, 58 had WHO grade III gliomas, and 67 were diagnosed clinically. Mutated IDH1 was predominantly observed in oligodendroglial tumors (WHO grade III). Patients with mutated IDH1 had a significantly better outcome than patients with wildtype IDH1: 2-year OS 59% and 18%, respectively (HR 0.38, 95% CI 0.21-0.68). However, when adjusting for other prognostic factors, IDH1 status was not a significant independent prognostic factor (HR=0.58, 95% CI 0.32-1.07). Young age, absence of neurological deficit, performance status 0-1, tumor not crossing the midline, and receiving post-surgical treatment were significant independent indicators of a good prognosis in multivariate analysis. IN
conclusionThis population-based study could not demonstrate IDH1 status to be an independent prognostic factor in high-grade gliomas when adjusting for the effect of classic prognostic factors.
Indexed as
Identifiers
23236540PMC3515987What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.